JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $31 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs
- Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
- Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating
- Agios up 13% at $33.50 after announcing pursuit of approval for mitapivat
- Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat